Sage Therapeutics, Inc. (NASDAQ:SAGE)‘s stock had its “buy” rating restated by Stifel Nicolaus in a research report issued on Friday. They presently have a $90.00 price target on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective points to a potential upside of 8.72% from the company’s previous close.
A number of other brokerages also recently issued reports on SAGE. Leerink Swann reaffirmed an “outperform” rating and set a $97.00 price target (up previously from $90.00) on shares of Sage Therapeutics in a report on Tuesday, June 20th. ValuEngine upgraded shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $82.00 price objective on shares of Sage Therapeutics in a research note on Tuesday, June 13th. BidaskClub upgraded shares of Sage Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 13th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $110.00 price objective on shares of Sage Therapeutics in a research note on Wednesday, May 10th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $85.82.
Shares of Sage Therapeutics (NASDAQ SAGE) opened at 82.78 on Friday. The company’s market cap is $3.09 billion. Sage Therapeutics has a 12 month low of $35.02 and a 12 month high of $88.93. The firm has a 50-day moving average of $73.34 and a 200 day moving average of $63.65.
Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.09. On average, analysts expect that Sage Therapeutics will post ($6.76) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://transcriptdaily.com/2017/07/18/sage-therapeutics-inc-nasdaqsage-stock-rating-reaffirmed-by-stifel-nicolaus.html.
A number of large investors have recently added to or reduced their stakes in SAGE. Fox Run Management L.L.C. purchased a new stake in Sage Therapeutics during the second quarter worth approximately $271,000. Goldman Sachs Group Inc. boosted its stake in Sage Therapeutics by 5.2% in the first quarter. Goldman Sachs Group Inc. now owns 161,867 shares of the biopharmaceutical company’s stock worth $11,504,000 after buying an additional 7,940 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in Sage Therapeutics by 512.9% in the first quarter. Point72 Asset Management L.P. now owns 395,300 shares of the biopharmaceutical company’s stock worth $28,094,000 after buying an additional 330,800 shares during the last quarter. Palo Alto Investors LLC boosted its stake in Sage Therapeutics by 9.1% in the first quarter. Palo Alto Investors LLC now owns 1,101,951 shares of the biopharmaceutical company’s stock worth $78,316,000 after buying an additional 92,021 shares during the last quarter. Finally, Fiduciary Trust Co. boosted its stake in Sage Therapeutics by 32.8% in the first quarter. Fiduciary Trust Co. now owns 10,884 shares of the biopharmaceutical company’s stock worth $774,000 after buying an additional 2,687 shares during the last quarter.
Sage Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.